These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: ddI and d4T plus protease inhibitors.
    Journal: GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012.
    Abstract:
    As a first-time regimen against HIV, treatment with zidovudine (AZT)/lamivudine (3TC) plus a protease inhibitor is not recommended. If resistance to 3TC develops, it could jeopardize the effectiveness of other subsequent drugs. In addition, peripheral neuropathy caused by didanosine (ddI), zalcitabine (ddC) or stavudine (d4T) is most commonly reported in late-stage AIDS patients, indicating that regimens including ddI, d4T, or ddC probably should be administered earlier in the course of disease. The relatively benign AZT/3TC combination should be reserved for more advanced patients. A recommended dosage schedule for ddI and d4T combined with indinavir is provided.
    [Abstract] [Full Text] [Related] [New Search]